Nitric oxide and superoxide dismutase modulate endothelial progenitor cell function in type 2 diabetes mellitus

• Main Authors: Brenner Benjamin, Hamed Saher, Aharon Anat, Daoud Deeb, Roguin Ariel
• Format: Article
• Language: English
• Published: BMC 2009-10-01
• Series: Cardiovascular Diabetology
• Online Access: http://www.cardiab.com/content/8/1/56

<p>Abstract</p> <p>Background</p> <p>The function of endothelial progenitor cells (EPCs), which are key cells in vascular repair, is impaired in diabetes mellitus. Nitric oxide (NO) and reactive oxygen species can regulate EPC functions. EPCs tolerate oxidative stress by upregulating superoxide dismutase (SOD), the enzyme that neutralizes superoxide anion (O₂^-). Therefore, we investigated the roles of NO and SOD in glucose-stressed EPCs.</p> <p>Methods</p> <p>The functions of circulating EPCs from patients with type 2 diabetes were compared to those from healthy individuals. Healthy EPCs were glucose-stressed, and then treated with insulin and/or SOD. We assessed O₂^-generation, NO production, SOD activity, and their ability to form colonies.</p> <p>Results</p> <p>EPCs from diabetic patients generated more O₂^-, had higher NAD(P)H oxidase and SOD activity, but lower NO bioavailability, and expressed higher mRNA and protein levels of p22-phox, and manganese SOD and copper/zinc SOD than those from the healthy individuals. Plasma glucose and HbA1c levels in the diabetic patients were correlated negatively with the NO production from their EPCs. SOD treatment of glucose-stressed EPCs attenuated O₂^-generation, restored NO production, and partially restored their ability to form colonies. Insulin treatment of glucose-stressed EPCs increased NO production, but did not change O₂^-generation and their ability to form colonies. However, their ability to produce NO and to form colonies was fully restored after combined SOD and insulin treatment.</p> <p>Conclusion</p> <p>Our data provide evidence that SOD may play an essential role in EPCs, and emphasize the important role of antioxidant therapy in type 2 diabetic patients.</p>